- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05403268
The EARLY DELTA Trial (EARLY DELTA)
The Impact of Early Delirium Detection With DeltaScan on Management of Underlying Delirium Causes in Critically Ill Patients. A Randomized Controlled Trial.
Rationale: Delirium is a type of acute encephalopathy that is triggered by an underlying somatic disorder. Patients experience disturbances in attention, alertness and other cognitive functions. In patients with delirium, a characteristic electroencephalography (EEG) pattern is seen, known as polymorphic delta activity. The MDR certified medical device "Deltascan" can detect this EEG pattern. Traditional clinical delirium screening instruments are known to have limited sensitivity, in particular for detecting hypoactive delirium. We hypothesize that adding EEG based encephalopathy detection to clinical observation scales increases the sensitivity and results in earlier detection of delirium and subsyndromal delirium, resulting in improved clinical outcomes of critically ill patients, such as delirium duration, ICU length of stay or survival.
Objective: This randomized controlled trial aims to study the effect of implementation of EEG based encephalopathy detection (DeltaScan, Prolira, Utrecht, The Netherlands, hereafter: DeltaScan) on relevant clinical endpoints (ICU length of stay, sedative requirements and delirium related complications, among others) in a mixed medical and surgical intensive care unit population.
Study design: a randomized controlled trial Study population: adult patients (>18 years) admitted to the ICU for unplanned care with a minimal anticipated ICU length of stay of 48h.
Intervention: either usual care, where the patients' medical team obtains regular delirium screening, versus usual care plus twice daily DeltaScan measurements. During the daily medical rounds, the DeltaScan results will be presented to the patients' medical team together with decision support, consisting of DeltaScan trend interpretation and protocol-based suggestions for evaluation of underlying delirium cause.
Main study parameters/endpoints: primary endpoint will be ICU length of stay. Secondary endpoints are encephalopathy/delirium occurrence, ICU encephalopathy/delirium free days, ventilator free days, organ support free days, sedative, opioid and antipsychotic drug requirement, delirium related complication occurrence, frequency and duration of physical restraints application, ICU mortality, ICU readmission, hospital length of stay, hospital mortality and 90-day mortality.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: In this study, it is not expected that randomization to the intervention group adds risk for patients. This is a study of a diagnostic intervention with additional encephalopathy/delirium observations consisting of a short (90 seconds) EEG measurement, which does not harm the patient. Clinicians will receive protocol-based decision support alongside the diagnostic observation. No additional medical treatments will be conducted as part of the study protocol.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Eline Pellekoorn, RN
- Phone Number: +31702104955
- Email: e.pellekoorn@hagaziekenhuis.nl
Study Locations
-
-
Overijssel
-
Enschede, Overijssel, Netherlands, 7512 KZ
- Not yet recruiting
- Medisch Spectrum Twente
-
Contact:
- Martin Rinket, RN
- Phone Number: +31 53 487 2000
- Email: researchic@mst.nl
-
Contact:
- Bert Beishuizen, MD, PhD
- Phone Number: +31 53 487 2000
- Email: b.beishuizen@mst.nl
-
Principal Investigator:
- Bert Beishuizen, MD PhD
-
-
Zuid Holland
-
Den Haag, Zuid Holland, Netherlands, 2545 AA
- Recruiting
- Hagaziekenhuis
-
Contact:
- Eline Pellekoorn, RN
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adult (18 years or above) admitted to ICU for any indication
- ICU length of stay anticipated to be 48h or longer from time of screening for inclusion
- Written informed consent by patient or representative
Exclusion Criteria:
- More than 48 hours have elapsed since the patient was first eligible to undergo a DeltaScan measurement after ICU admission. A patient is eligible for DeltaScan measurements if they are a. able to cooperate with simple instructions AND b. are alert or mildly sedated no deeper than a Richmond Agitation and Sedation Score of -2.
- Admission for out-of-hospital cardiac arrest, status epilepticus, hemorrhagic or ischemic stroke, increased intracranial pressure, head trauma
- Recent intracranial neurosurgery (<30 days prior to inclusion)
- Known space-occupying lesions in the brain or skull
- Metal implants in brain or skull
- Diagnosis of dementia or Parkinson's disease
- Inpatient from nursing home
- Lithium use (<30 days prior to inclusion)
- Imminent death or palliative care phase
- Patients ánd their legal representatives both do not understand Dutch or English
- Patients who participated in the EARLY DELTRA trial <90 days ago
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Sham Comparator: Usual Care
Usual care group.
Participants undergo twice daily DeltaScan measurements in addition to usual care.
An adapted device is used, that masks the measurement result (it generates a QR-code, that is scanned into the patient data management system).
The results will be unblinded one enrollment is complete.
|
Twice daily DeltaScan observations
Other Names:
|
Experimental: Usual Care + DeltaScan
Intervention group.
Participants undergo twice daily DeltaScan measurements in addition to usual care.
The measurement result is used together with routine delirium screening observations to guide management, according to the local delirium protocol.
|
Twice daily DeltaScan observations
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ICU length of stay
Time Frame: Assessed at the 90 day post discharge follow-up
|
Length of stay in the intensive care unit, measured in hours
|
Assessed at the 90 day post discharge follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Encephalopathy/delirium occurrence (DeltaScan)
Time Frame: Assessed daily, until participant is discharged from ICU, or until the maximum observation time (30 days)
|
Defined as: any DeltaScan score ≥ 3 OR initiation of antipsychotic treatment
|
Assessed daily, until participant is discharged from ICU, or until the maximum observation time (30 days)
|
Delirium occurrence (ICDSC)
Time Frame: Assessed daily, until participant is discharged from ICU, or until the maximum observation time (30 days)
|
Defined as: any ICDSC score ≥ 4 OR initiation of antipsychotic treatment
|
Assessed daily, until participant is discharged from ICU, or until the maximum observation time (30 days)
|
ICU encephalopathy/delirium and coma free days (reported as: composite, delirium free days, coma free days)
Time Frame: Assessed at the 14th day after ICU admission. If the patient dies during the first 14 days of the study observation period, this outcome is assessed at the date of death
|
Defined as: the number of days in the first 14 days after the patient was randomized during which the patient was alive without delirium or coma.
We will calculate this value separately based on DeltaScan alone, DeltaScan+ICDSC and ICDSC alone)
|
Assessed at the 14th day after ICU admission. If the patient dies during the first 14 days of the study observation period, this outcome is assessed at the date of death
|
ICU ventilator free days
Time Frame: Assessed at the 14th day after ICU admission. If the patient dies during the first 14 days of the study observation period, this outcome is assessed at the date of death
|
Defined as: the number of days in the first 14 days after the patient was randomized during which the patient was alive without mechanical ventilation, regardless of ventilation mode or route.
High-flow nasal oxygen (HFNO) will not be regarded as ventilation.
If patients are ventilated with a device provided by another institute (i.e.
Centrum voor Thuisbeademing), only days spent on the ICU ventilator will be counted.
Any day with <12h of mechanical ventilation will be counted as 0,5 day.
More than 12h of mechanical ventilation will be counted as 1 day
|
Assessed at the 14th day after ICU admission. If the patient dies during the first 14 days of the study observation period, this outcome is assessed at the date of death
|
ICU organ support free days
Time Frame: Assessed at the 14th day after ICU admission. If the patient dies during the first 14 days of the study observation period, this outcome is assessed at the date of death
|
Defined as: the number of days in the first 14 days after the patient was randomized during which the patient was alive without mechanical ventilation (any modality), HFNO, renal replacement therapy (any modality), mechanical circulatory support (ECLS, IABP, Impella), intravenous inotropes (dobutamine, milrinone, enoximone, levosimendan) or vasopressors (noradrenalin > 0.25 mcg/kg/min or any dose of terlipressin / arginine vasopressin)
|
Assessed at the 14th day after ICU admission. If the patient dies during the first 14 days of the study observation period, this outcome is assessed at the date of death
|
ICU mortality rate
Time Frame: This is assessed at the date of death. In ICU survivors, it is assessed at the 90 day post-discharge follow-up
|
Defined as death occurring before ICU discharge.
Outcome reported as proportion of participants who died before ICU discharge.
|
This is assessed at the date of death. In ICU survivors, it is assessed at the 90 day post-discharge follow-up
|
ICU readmission rate
Time Frame: This outcome is only scored when an unplanned re-admission occurs within the first 90 days after ICU discharge.
|
Unplanned re-admission to the ICU before hospital discharge.
Outcome reported as proportion of participants who were re-admitted to ICU before hospital discharge.
|
This outcome is only scored when an unplanned re-admission occurs within the first 90 days after ICU discharge.
|
Hospital length-of-stay
Time Frame: Assessed at the 90 day post-discharge follow-up
|
Outcome reported in days
|
Assessed at the 90 day post-discharge follow-up
|
Hospital mortality rate
Time Frame: This is assessed at the date of death. In survivors, it is assessed at the 90 day post-discharge follow-up
|
Defined as death occurring before hospital discharge.
Outcome reported as proportion of participants who died before hospital discharge.
|
This is assessed at the date of death. In survivors, it is assessed at the 90 day post-discharge follow-up
|
90 day mortality rate
Time Frame: Assessed at the 90 day post-discharge follow-up
|
Defined as death occurring within 90 days after study enrollment.
Outcome reported as proportion of participants who died before 90d follow-up
|
Assessed at the 90 day post-discharge follow-up
|
ICU Sedative Drug requirement
Time Frame: Assessed daily, until participant is discharged from ICU, or until the maximum observation time (30 days)
|
The cumulative doses of the following sedative drugs, administered after randomisation: propofol, clonidine, dexmedetomidine, esketamine, zopiclone, benzodiazepines
|
Assessed daily, until participant is discharged from ICU, or until the maximum observation time (30 days)
|
ICU opioid requirement
Time Frame: Assessed daily, until participant is discharged from ICU, or until the maximum observation time (30 days)
|
The cumulative doses of opioids, administered after randomisation
|
Assessed daily, until participant is discharged from ICU, or until the maximum observation time (30 days)
|
ICU antipsychotic drug requirement
Time Frame: Assessed at ICU Assessed daily, until participant is discharged from ICU, or until the maximum observation time (30 days)
|
cumulative dose of the following antipsychotic drugs, administered after randomisation: haloperidol, quetiapine, other antipsychotic drugs
|
Assessed at ICU Assessed daily, until participant is discharged from ICU, or until the maximum observation time (30 days)
|
ICU accidental device removal incidence and falls
Time Frame: Assessed daily, until participant is discharged from ICU, or until the maximum observation time (30 days)
|
Defined as the number of incidents where a patient accidentally removes an indwelling catheter, tube, infusion line or drain (e.g.
intravenous lines, wound drains, airway device, feeding tubes etc) or falls out of bed
|
Assessed daily, until participant is discharged from ICU, or until the maximum observation time (30 days)
|
ICU incidence and duration of the use of physical restraints
Time Frame: Assessed daily, until participant is discharged from ICU, or until the maximum observation time (30 days)
|
Defined as the frequency of application of physical restraints and the cumulative duration of restraint application during ICU admission
|
Assessed daily, until participant is discharged from ICU, or until the maximum observation time (30 days)
|
Self-assessed quality of life
Time Frame: Assessed one year after ICU discharge
|
Self-assessed quality of life measured with the Euroqol Quality of Life questionnaire, version EQ6D
|
Assessed one year after ICU discharge
|
Self assessed cognitive function
Time Frame: Assessed one year after ICU discharge
|
Self-assessed cognitive function measured with the cognitive failure questionnaire (CFQ, Merckelbach, Muris & Nijman 1996)
|
Assessed one year after ICU discharge
|
Self assessed mood and depression symptoms
Time Frame: Assessed one year after ICU discharge
|
Self assessed mood and depression symptoms measured with the Patient Health Questionnaire (PHQ-9)
|
Assessed one year after ICU discharge
|
Self assessed mobility and physical functioning
Time Frame: Assessed one year after ICU discharge
|
Self assessed mobility and physical functioning measured with the Barthel Index
|
Assessed one year after ICU discharge
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Thomas H Ottens, MD, MSc, PhD, Hagaziekenhuis
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- T21-064
- NL78854.041.21 (Registry Identifier: CCMO Toetsingonline)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Delirium
-
Efficacy Care R&D LtdHadassah Medical OrganizationUnknownDelirium | Delirium, Cause Unknown | Delirium of Mixed Origin | Delirium Confusional State | Delirium Drug-InducedIsrael
-
Imperial College Healthcare NHS TrustRecruitingCardiac Surgery | Intensive Care Unit Delirium | Post Operative DeliriumUnited Kingdom
-
Oslo University HospitalUniversity of Melbourne; Norwegian Academy of MusicCompletedDelirium in Old Age | Delirium of Mixed Origin | Delirium Superimposed on Dementia | Delirium Confusional StateNorway
-
Universidad de SantanderUnknownDelirium of Mixed Origin | Hypoactive Delirium | Hyperactive DeliriumColombia
-
Menoufia UniversityCompleted
-
Chinese PLA General HospitalBeijing Tiantan HospitalRecruiting
-
Charite University, Berlin, GermanyBARMERRecruitingDelirium in Old AgeGermany
-
Mayo ClinicCompletedPost-Operative DeliriumUnited States
-
Johns Hopkins UniversityNational Institute on Aging (NIA)Active, not recruitingDelirium | Delirium on Emergence | Hearing Loss | Hearing Loss, High-Frequency | Hearing Loss, Sensorineural | Delirium, Cause Unknown | Hearing Loss, Bilateral | Hearing Disability | Delirium in Old Age | Delirium of Mixed Origin | Delirium Superimposed on Dementia | Delirium Confusional State | Delirium With... and other conditionsUnited States
-
Qin ZhangNational Natural Science Foundation of ChinaRecruiting
Clinical Trials on DeltaScan
-
Catharina Ziekenhuis EindhovenCompletedDelirium | Cognitive Impairment | Cognitive Dysfunction | Postoperative Delirium | Delirium in Old Age | Cognitive Dysfunction, PostoperativeNetherlands